Infrastructure at Scale: A Conversation with Germfree’s New CEO
May 26, 2026
We speak with Carol Houts about advanced therapy manufacturing, modular cleanrooms, and the challenge of scaling GMP infrastructure
7 min read
False
Advertisement
Interviews
Cell Therapy Manufacturing: A Medicine Maker’s “Dream”
May 25, 2026
Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems
13 min read
Interphex Insider: The Future-Ready Biomanufacturing Facility
May 15, 2026
Meg Carr reflects on the key themes from this year’s show – from contamination control and AI to flexible facility design
3 min read
Jonathan Van-Tam on COVID’s Next Phase
By James Strachan, Julian Upton
April 14, 2026
Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19
4 min read
What I Learned Bringing Slalom Chromatography Back from the Dead
March 25, 2026
Fabrice Gritti spent a year immersed in the world of DNA physics to resurrect a long-abandoned technique to solve modern challenges in cell and gene therapy analysis
6 min read
Building Quality into Advanced Therapies from Day One
March 13, 2026
Why early, risk-based thinking is critical in cell and gene therapy development
5 min read
The New Blueprint for Vaccine Development
March 12, 2026
ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness
5 min read
What Does Corporate Compliance Really Mean?
By Stephanie Vine
March 10, 2026
Corporate compliance isn’t just about avoiding fines; it’s an opportunity to shape culture, partnerships, and everyday decision-making
10 min read
Solving the Problem of Insolubility: Part III
March 3, 2026
Exploring new applications for KinetiSol and the evolving role of CDMOs in bringing the next generation of complex molecules to patients
4 min read
Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D
February 25, 2026
A Q&A with iXCells Biotechnologies CEO, Steve Smith
8 min read
